236 related articles for article (PubMed ID: 11741655)
1. Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam G; Edwards J
Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
[No Abstract] [Full Text] [Related]
2. Imatinib for chronic myeloid leukaemia: a NICE mess.
Barbour V
Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
[No Abstract] [Full Text] [Related]
3. Imatinib for chronic myeloid leukaemia: a NICE mess.
O'Brien SG
Lancet; 2001 Dec; 358(9296):1902-3. PubMed ID: 11741654
[No Abstract] [Full Text] [Related]
4. Imatinib for chronic myeloid leukaemia: a NICE mess.
Lim D; Muir J
Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
[No Abstract] [Full Text] [Related]
5. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside R; Round A; Dalziel K; Stein K; Royle P
Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
[No Abstract] [Full Text] [Related]
6. NICE backs leukaemia drug after manufacturer drops price.
Wise J
BMJ; 2012 Mar; 344():e2274. PubMed ID: 22442356
[No Abstract] [Full Text] [Related]
7. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
8. Position paper on imatinib mesylate in chronic myeloid leukaemia.
O'Brien SG; Rule SA
Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
[No Abstract] [Full Text] [Related]
9. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
10. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
Goldman J
Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
[No Abstract] [Full Text] [Related]
11. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
Dalziel K; Round A; Garside R; Stein K
Pharmacoeconomics; 2005; 23(5):515-26. PubMed ID: 15896102
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelogenous leukemia.
Klemm J; Mehr SR
Am J Manag Care; 2012 May; 18(3 Spec No.):SP105-7. PubMed ID: 22642273
[No Abstract] [Full Text] [Related]
13. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
[TBL] [Abstract][Full Text] [Related]
14. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
Mesa RA; Steensma DP; Hoyer J; Ketterling RP
Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
[No Abstract] [Full Text] [Related]
15. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
Dalziel K; Round A; Stein K; Garside R; Price A
Health Technol Assess; 2004 Jul; 8(28):iii, 1-120. PubMed ID: 15245690
[TBL] [Abstract][Full Text] [Related]
16. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
[No Abstract] [Full Text] [Related]
17. NICE widens patient group for leukaemia drug.
Kmietowicz Z;
BMJ; 2002 Oct; 325(7369):852. PubMed ID: 12386018
[No Abstract] [Full Text] [Related]
18. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
19. Doctors condemn NICE's guidance on leukaemia drug.
Mayor S
BMJ; 2002 Jun; 324(7350):1352. PubMed ID: 12052793
[No Abstract] [Full Text] [Related]
20. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
